Table 1.
Characteristics of study patients.
| STOP-Bang < 3 (n = 95) | STOP-Bang ≥ 3 (n = 195) | P Value | |
|---|---|---|---|
| Patient characteristics | |||
| Age, years | 65 [56–72] | 65 [58–73] | 0.14 |
| Male sex | 42 (44.2) | 140 (71.8) | < 0.001 |
| BMI, kg/m2 | 21.6 ± 2.9 | 23.7 ± 3.3 | < 0.001 |
| Smoking | 0.003 | ||
| Never-smoker | 54 (56.8) | 72 (36.9) | |
| Former smoker | 22 (23.2) | 79 (40.5) | |
| Current smoker | 19 (20.0) | 44 (22.6) | |
| Hospitalization | > 0.99 | ||
| Inpatients | 92 (96.8) | 189 (96.9) | |
| Outpatients | 3 (3.2) | 6 (3.1) | |
| ASA physical status | 0.09 | ||
| I | 0 (0.0) | 0 (0.0) | |
| II | 68 (71.6) | 120 (61.5) | |
| III | 27 (28.4) | 75 (38.5) | |
| Comorbidity | |||
| Hypertension | 15 (15.8) | 113 (58.0) | < 0.001 |
| Diabetes mellitus | 8 (8.4) | 51 (26.2) | < 0.001 |
| Coronary heart disease | 6 (6.3) | 19 (9.7) | 0.33 |
| Cerebrovascular disease | 2 (2.1) | 11 (5.6) | 0.23 |
| COPD | 19 (20.0) | 42 (21.5) | 0.76 |
| Asthma | 4 (4.2) | 8 (4.1) | > 0.99 |
| Chronic kidney disease | 3 (3.2) | 10 (5.1) | 0.56 |
| Chronic liver disease | 6 (6.3) | 7 (3.6) | 0.37 |
| Lung cancer | 37 (39.0) | 105 (53.9) | 0.02 |
| Modified Mallampati score | 0.78 | ||
| I | 32 (34.0) | 58 (30.2) | |
| II | 36 (38.3) | 75 (39.1) | |
| III/IV | 26 (27.7) | 59 (30.7) | |
| Neck circumference, cm | 33.5 [32.0–36.0] | 37.0 [34.5–39.5] | < 0.001 |
| Baseline SBP, mm Hg | 127 [117–149] | 134 [119–147] | 0.28 |
| Baseline heart rate, beats/min | 76 [65–82] | 72 [65–81] | 0.58 |
| Baseline SpO2, % | 99 [98–100] | 99 [97–100] | 0.15 |
| Snoring under sedation | 22 (23.7) | 65 (34.2) | 0.07 |
| Procedural characteristics | |||
| Sedation time, min | 9 [7–12] | 10 [7–13] | 0.95 |
| Procedure time, min | 6 [4–9] | 6 [4–9] | 0.88 |
| Bronchial washing | 78 (82.1) | 135 (69.2) | 0.02 |
| Endobronchial biopsy | 16 (16.8) | 38 (19.5) | 0.59 |
| Bronchial brushing | 0 (0.0) | 1 (0.5) | > 0.99 |
| Transbronchial lung biopsy | 0 (0.0) | 3 (1.5) | 0.55 |
| Pharmacological characteristics | |||
| Total dose of midazolam, mg | 5 [3–5] | 5 [3–5] | 0.80 |
| Administration of 50 mcg of fentanyl | 6 (6.3) | 15 (7.7) | 0.67 |
Data are presented as No. (%), mean ± SD, or median [interquartile range].
ASA American Society of Anesthesiologists, BMI body mass index, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, SpO2 pulse oximeter oxygen saturation.